• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Dewhurst Martin William

    2/4/26 7:30:21 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TTRX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Dewhurst Martin William

    (Last) (First) (Middle)
    C/O TURN THERAPEUTICS INC.
    250 N. WESTLAKE BLVD.

    (Street)
    WESTLAKE VILLAGE CA 91362

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/07/2026
    3. Issuer Name and Ticker or Trading Symbol
    Turn Therapeutics Inc. [ TTRX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) (1) 07/26/2034 Common Stock 40,030(2) $4.59(2) D
    Explanation of Responses:
    1. The stock option became exercisable as to 10,000 of the shares of common stock on July 26, 2024, and 858 shares on the last day of each month thereafter, in each case, after giving effect to the stock split as described below.
    2. The number of shares of common stock underlying the stock option and the applicable exercise price give effect to the 2-for-1 forward stock split, that took effect on September 30, 2025.
    Remarks:
    Exhibit 24 - Power of Attorney.
    /s/ Zuraiz Chaudhary, attorney-in-fact for Martin William Dewhurst 02/04/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TTRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TTRX

    DatePrice TargetRatingAnalyst
    12/29/2025$8.00Buy
    D. Boral Capital
    More analyst ratings

    $TTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Turn Therapeutics with a new price target

    D. Boral Capital initiated coverage of Turn Therapeutics with a rating of Buy and set a new price target of $8.00

    12/29/25 7:11:36 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    SEC Filings

    View All

    Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Turn Therapeutics Inc. (0002023016) (Filer)

    2/9/26 8:44:24 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Turn Therapeutics Inc. (0002023016) (Filer)

    1/12/26 8:12:12 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Turn Therapeutics Inc. (0002023016) (Filer)

    1/7/26 4:18:35 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences

    Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief Executive Officer, will present at the 46th Annual TD Cowen Healthcare Conference and the 36th Annual Oppenheimer Healthcare Life Sciences Conference. The Company will provide an update on its dermatology pipeline, including the status of the ongoing Phase 2 clinical trial evaluating GX-03, the company's lead investigational therapy for moderate-to-severe atopic dermatitis (eczema). Management will also participate in one-on-one meetings with institutional investors. Conference Participation: 36

    2/9/26 8:00:00 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

    Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026 Appointment of Martin Dewhurst, a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directors Expansion of intranasal vaccine pipeline to include intranasal Influenza candidate that may stimulate systemic immunity via targeted intranasal exposure without adjuvants or potentially harmful additives Progress on commercial partnerships with expected revenue generation in 2026 in advanced wound care market Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and

    1/12/26 8:05:00 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

    LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings more than 30 years of global leadership experience in life sciences, with a particular focus on mergers and acquisitions. "Martin's appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation," said Bradley Burnam, Chief Executive Office

    1/7/26 4:05:00 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dewhurst Martin William was granted 21,882 shares (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    2/4/26 7:31:02 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dewhurst Martin William

    3 - Turn Therapeutics Inc. (0002023016) (Issuer)

    2/4/26 7:30:21 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Chaudhary Zuraiz bought $8,750 worth of shares (2,500 units at $3.50), increasing direct ownership by 25% to 12,500 units (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    12/12/25 6:00:02 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Chaudhary Zuraiz bought $8,750 worth of shares (2,500 units at $3.50), increasing direct ownership by 25% to 12,500 units (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    12/12/25 6:00:02 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Golden Arthur F bought $33,946 worth of shares (9,868 units at $3.44), increasing direct ownership by 19% to 60,602 units (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    11/25/25 9:00:22 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Chaudhary Zuraiz bought $7,074 worth of shares (2,450 units at $2.89), increasing direct ownership by 32% to 10,000 units (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    11/21/25 5:43:52 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    Leadership Updates

    Live Leadership Updates

    View All

    Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

    Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026 Appointment of Martin Dewhurst, a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directors Expansion of intranasal vaccine pipeline to include intranasal Influenza candidate that may stimulate systemic immunity via targeted intranasal exposure without adjuvants or potentially harmful additives Progress on commercial partnerships with expected revenue generation in 2026 in advanced wound care market Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and

    1/12/26 8:05:00 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

    LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings more than 30 years of global leadership experience in life sciences, with a particular focus on mergers and acquisitions. "Martin's appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation," said Bradley Burnam, Chief Executive Office

    1/7/26 4:05:00 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications

    LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company's licensing and partnership initiatives. "We are thrilled to welcome Andrew to this newly created senior executive role. His addition comes as Turn Therapeutics enters a new phase of growth following its public listing and strengthened balance sheet. Andrew

    11/4/25 5:07:26 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care